Dithiolethiones for cancer chemoprevention: where do we stand?

Area of Science:

• Medicinal Chemistry
• Cancer Research
• Molecular Biology

Background:

• Dithiolethiones are recognized cancer chemopreventive agents.
• Their primary mechanism involves Nrf2 signaling activation and phase II enzyme induction.
• Oltipraz, a prominent dithiolethione, demonstrated broad-spectrum chemopreventive activity in preclinical models but faced challenges in clinical efficacy and safety.

Purpose of the Study:

• To identify and investigate novel dithiolethiones with enhanced chemopreventive properties.
• To evaluate their efficacy in inducing phase II enzymes and inhibiting chemical carcinogenesis.
• To assess their organ specificity and potential for safe human application.

Main Methods:

• Preclinical studies evaluating novel dithiolethione compounds.
• Assessment of Nrf2 signaling activation and phase II enzyme induction.
• In vivo testing for inhibition of chemical carcinogenesis and organ specificity.

Main Results:

• Identification of dithiolethiones significantly more potent than oltipraz.
• Demonstrated superior induction of phase II enzymes and inhibition of chemical carcinogenesis in preclinical models.
• Observed pronounced organ specificity for these novel compounds in vivo.

Conclusions:

• Novel dithiolethiones represent a promising class of compounds for cancer chemoprevention.
• These agents exhibit enhanced efficacy and potency compared to oltipraz.
• Further research into these specific dithiolethiones may yield effective and safe human cancer prevention therapies.